Mark Auerbach

Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY.

Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY.

Endo Generics Holdings, Inc. develops, manufactures, and markets generic pharmaceutical products. It also offers dosage, branded, and generic sterile injectable products. The company was founded in 1978 and is headquartered in New York, NY.

Aretec Group, Inc. is a holding company, which engages in the provision of integrated financial services focusing on retail investors. The company was founded on December 27, 2012 and is headquartered in El Segundo, CA.

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. It also focuses on developing novel drugs to solve pandemic-sized problems like the coronavirus disease. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA.